This week I posted the review from the European Journal of Haematology, The heart in transfusion dependent homozygous thalassaemia today. The review strongly supports combination chelation using desferal and deferiprone (L1) for reducing iron overload and especially for use in patients with iron overload in their hearts. It has been shown to be the best way to quickly reduce iron overload and remove thal patients from immediate danger.
A real eye opener in this review is that iron overload in the heart cannot be accurately predicted by testing serum ferritin or liver iron. This is major news concerning liver iron, as it was always thought that if liver iron is low, heart iron will also be low. This was not what this review found. Heart iron needs to be directly tested.
What has really made me think this week is learning that the person who sent me this review is now on combination chelation because she found out she is suffering from iron overload in the heart. She has had excellent care and was one of the first people I knew to be on an Exjade trial. She has complied with chelation, yet still has iron overload in her heart. She and I are both optimistic that the combination therapy will quickly reduce this iron load. But the questions remain. If a patient who has excellent care and monitoring can find herself with iron overload in the heart, shouldn't all patients have their hearts tested for iron overload, regardless of their perceived health and measured iron loads? I realize these tests are not readily available to many patients but shouldn't one of the goals of the international organization be to make these tests available? Patients need to know and the international thal community needs to do more to make sure patients know their true status and also have ready access to chelators. (I find it disgraceful that L1 is not easily available to patients in the US and Canada).
Once again, the link to the review is at
http://www.thalassemiapatientsandfriends.com/index.php?topic=1451.msg11816#msg11816